- Details
- In this Society of Nuclear Medicine and Molecular Imaging- Special Session during the 2021 LUGPA CME presentations, Dr Steven Rowe discusses a number of different scenarios that we might encounter clinically where conventional imaging is clearly being replaced by PSMA based imaging. In the last part of his talk, Dr. Rowe focuses on some future directions where PSMA PET may have some interesting th...
|
- Details
- In this 2021 LUGPA MCE presentation, Noah Hahn presents Systemic Therapies in Advanced Bladder Cancer. He reviews the current data and experiences with immune checkpoint inhibitor therapies, (ICI) targeted therapies, and antibody-drug conjugate (ADC) therapies. Biographies: Noah M. Hahn, MD, Professor of Oncology and Urology, Department of Oncology and Urology, Johns Hopkins University School of M...
|
- Details
- In this LUGPA CME presentation, Dr Steven Kaplan presents minimally invasive options for treating benign prostatic hyperplasia (BPH). Dr. Kaplan's presentation is fueled by a low adherence rate to medications, long-term side effects with medication use, and the importance of minimally invasive treatments for long-term overall quality of life. He focused his talk on novel treatments for BPH and the...
|
- Details
- In this 2021 LUGPA CME presentation, Dr Briana Walton presents urogynecology controversies, the current landscape of female pelvic medicine, and reconstructive surgery. She focuses on issues that reconstructive surgeons are facing and how the landscape of treatment for disorders of the pelvic floor is shifting as women are demanding different care. Biographies: Briana Walton, MD, Female Pelvic Med...
|
- Details
- In this 2021 Large Urology Group Practice Association Annual Meeting presentation James Wysock discusses imaging of the prostate, high and low-frequency ultrasound versus MRI, and where this area is going in the landscape of prostate cancer management specifically how to improve our screening and how to select men for treatment. Biographies: James S. Wysock, MD, MS, Associate Professor, NYU Langon...
|
- Details
- In this 2021 LUGPA CME presentation, Michael O’Donnell discusses intravesical therapies for non-muscle invasive disease. He covers the background of indications for intravesical therapy, managing recurrent non-muscle invasive bladder cancer (NMIBC) including BCG failures and BCG unresponsiveness. Biographies: Michael A. O’Donnell, MD, Richard D. Williams Professor & Director of Urologic Oncology,...
|
- Details
- In this 2021 LUGPA presentation, Noah Hahn presents " Biomarkers and Next-Generation Sequencing in Advanced Bladder Cancer Patients" . Dr. Hahn discusses the differences in prognostic biomarkers and predictive biomarkers before discussing PD-L1 on the immunohistochemistry side, sequencing biomarkers, tumor mutational burden, and microsatellite instability or mismatch repair deficient tumors. Biogr...
|
- Details
- In this LUGPA CME presentation, Dr Emmanuel Antonarakis discussed genomic profiling, germline, and somatic testing in the landscape of prostate cancer. He discusses what are germline mutations, what are somatic mutations, how common they are in prostate cancer as well as who should be tested for these mutations. Dr. Antonarakis guides the views through a genomics report, a next-generation sequenci...
|
- Details
- In this LUGPA CME presentation, Dr Phillip Kuo presents theranostics and its role in prostate cancer treatment. He provides a brief introduction into theranostics, a focus on PSMA, highlighting some select theranostic trials, then delves into a broader vision of what theranostics can mean, particularly to the nuclear medicine committee and PSMA. Biographies: Phillip H. Kuo, MD, Ph.D., Professor of...
|
- Details
- Reported on March 26, 2020 New provisions expand telemedicine services during the current COVID-19 pandemic in the United States. Neal Shore hosts a discussion with Drs. Gary Kirsh and Deepak Kapoor, and Political Consultants for Health Policy, Tracy Spicer, and John McManus. Previously, Medicare reimbursement for telehealth was highly restricted both in terms of eligibility and reimbursement rate...
|
